BACKGROUND: Human papillomavirus (HPV) positivity improves prognosis in patients with oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other biomarkers may improve its prognostic power. METHODS: The approach was a literature search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta-analysis. RESULTS: In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion criteria. On meta-analysis, there was a significant overall survival (OS) benefit for patients with HPV positive and p16 positive tumors. There was some evidence of improved OS of OPSCC patients with raised bcl2; amplification of 11q3 and loss of 16q genes; and low c-met, ki67, IMD, PLK, FHIT, nuclear surviving, or nuclear cyclin D1. However, none of these was suitable for meta-analysis. CONCLUSION: Survival from OPSCC is associated with several biomarkers, which constitute potential targets for research into improving the prognostic power of HPV in OPSCC. Larger trials are needed, with standardization of cut-points and adherence to consensus reporting guidelines.
BACKGROUND:Human papillomavirus (HPV) positivity improves prognosis in patients with oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other biomarkers may improve its prognostic power. METHODS: The approach was a literature search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta-analysis. RESULTS: In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion criteria. On meta-analysis, there was a significant overall survival (OS) benefit for patients with HPV positive and p16 positive tumors. There was some evidence of improved OS of OPSCC patients with raised bcl2; amplification of 11q3 and loss of 16q genes; and low c-met, ki67, IMD, PLK, FHIT, nuclear surviving, or nuclear cyclin D1. However, none of these was suitable for meta-analysis. CONCLUSION: Survival from OPSCC is associated with several biomarkers, which constitute potential targets for research into improving the prognostic power of HPV in OPSCC. Larger trials are needed, with standardization of cut-points and adherence to consensus reporting guidelines.
Authors: Margret Rave-Fränk; Narges Tehrany; Julia Kitz; Martin Leu; Hanne Elisabeth Weber; Peter Burfeind; Henning Schliephake; Martin Canis; Tim Beissbarth; Holger Michael Reichardt; Hendrik Andreas Wolff Journal: Strahlenther Onkol Date: 2015-09-15 Impact factor: 3.621
Authors: Gypsyamber D'Souza; Devasena Anantharaman; Tarik Gheit; Behnoush Abedi-Ardekani; Daniel C Beachler; David I Conway; Andrew F Olshan; Victor Wunsch-Filho; Tatiana N Toporcov; Wolfgang Ahrens; Kathy Wisniewski; Franco Merletti; Stefania Boccia; Eloiza H Tajara; Jose P Zevallos; José Eduardo Levi; Mark C Weissler; Sylvia Wright; Ghislaine Scelo; Angela L Mazul; Massimo Tommasino; Gabriella Cadoni; Paul Brennan Journal: Oral Oncol Date: 2016-09-26 Impact factor: 5.337
Authors: Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers Journal: Eur Arch Otorhinolaryngol Date: 2015-07-31 Impact factor: 2.503
Authors: Robbie Woods; Esther M O'Regan; Susan Kennedy; Cara Martin; John J O'Leary; Conrad Timon Journal: World J Clin Cases Date: 2014-06-16 Impact factor: 1.337